NRC Form 374
(5-84)

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Amendment No. 03

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. St. Luke's Regional Medical Center	In accordance with application dated March 15, 1985 3. License number 14-18721-01 is amended in its entirety to read as follows:
2. 2720 Stone Park Blvd. Sioux City, IA 51104	4. Expiration date: October 31, 1990
	5. Docket or Reference No.: 030-14084

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35	A. As necessary for uses authorized in Subitem 9.A
B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35	B. 3 curies of each byproduct material authorized in Subitem 6.B
C. Any byproduct material listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. Any radiopharmaceutical listed in Group IV of Schedule A, Section 35.100 of 10 CFR 35	C. As necessary for uses authorized in Subitem 9.C
D. Any byproduct material listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. Any radiopharmaceutical listed in Group V of Schedule A, Section 35.100 of 10 CFR 35	D. As necessary for uses authorized in Subitem 9.D
E. Any byproduct material listed in Group VI of Schedule A, Section 35.100 of 10 CFR 35	E. Any sealed source listed in Group VI of Schedule A, Section 35.100 of 10 CFR 35	E. 2 curies total for all sources authorized in Subitem 6.E

COPY 2

BS 10/18/85

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number: 14-18721-01

Docket or Reference number: 030-14084

Amendment No. 03

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
F. Xenon-133	F. Gas or gas in solution that is the subject of an active (i.e., not withdrawn or terminated) "New Drug Application" (NDA) approved by FDA or an active (i.e., not withdrawn, terminated or on "clinical hold") "Notice of Claimed Investigational Exemption for a New Drug" (IND) that has been accepted by FDA	F. 200 millicuries

9. Authorized Use

A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

C. Any therapeutic procedure listed in Group IV of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

D. Any therapeutic procedure listed in Group V of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

E. Any procedure listed in Group VI of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

F. Blood flow studies. Pulmonary function studies.

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at 2720 Stone Park Blvd., Sioux City, Iowa.

11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."

COPY

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
- 14-18721-01

Docket or Reference number
030-14084

Amendment No. 03

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

O. E. Sleander, M.D.	Groups I, II, III, IV, V and VI Xenon-133
W. S. Thomas, M.D.	Groups I, II, III, IV, V and VI Xenon-133
C. M. Havvoitt, M.D.	Groups I, II, III, IV, V and VI Xenon-133
J. J. Goeber, M.D.	Groups I, II and III Iodine-131 for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma
D. L. Howard, M.D.	Groups I, II and III Iodine-131 for treatment of hyperthyoridism or cardiac dysfunction
Daryle C. Rife, M.D.	Groups I, II and III Xenon-133 Iodine-131 for treatment of hyperthyroidism, cardiac dysfunction and thyroid carcinoma Phosphorus-32 as colloidal chromic phosphate for intracavitary treatment

13. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:

A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of ten (10) half-lives.

B. Prior to disposal as normal waste, radioactive waste shall be monitored to determine that its radioactivity cannot be distinguished from background with typical low-level laboratory survey instruments. All radiation labels will be removed or obliterated.

C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

14. Licensed material shall be used in accordance with the provisions of Section 35.14(b)(c)(e) and (f) of Title 10, Code of Federal Regulations.

15. Patients containing Iodine 131 for the treatment of thyroid carcinoma (or patients containing therapeutic quantities of Gold 198) shall remain hospitalized until the residual activity is 30 millicuries or less.

COPY

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number
-14-18721-01

Docket or Reference number
030-14084

Amendment No. 03

16. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated March 15, 1985; letter dated May 20, 1985; and ALARA Program dated March 1985. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

For the U.S. Nuclear Regulatory Commission

Date OCT 18 1985

Original Signed
By William J. Adam, Ph.D.
Materials Licensing Section, Region III

COPY